Hemolysis is caused by hemolysins produced by microorganisms, which causes the breakdown of red blood cells in human blood and has adverse effects on human health. To support and accelerate your live biotherapeutic drug discovery, Creative Biolabs will work with you to provide fast and high-quality hemolytic activity test services for the safety evaluation of your live biotherapeutic products.
Hemolysis refers to the lysis of red blood cells (erythrocytes) and the release of intracellular hemoglobin. Microbial hemolysis occurs mainly caused by hemolysins, lipid, or protein virulence factors produced by bacteria. The main function of these hemolysins is that enables bacteria to utilize nutrients release from the host erythrocytes through hemolysis. Such as iron ion, an essential factor in the growth of some bacteria, presents at low concentrations outside the cells but rich in iron-containing hemoglobin in erythrocytes.
Microbial hemolysis is divided into α-hemolysis, β-hemolysis, and γ-hemolysis according to the ability of bacteria to lyse erythrocytes. Hemolytic activity test can be used for the identification of the classification of some microorganisms, such as Streptococcus species, and more importantly, is utilized for the safety assessment of live biotherapeutic products in vitro.
Hemolytic activity test for live biotherapeutic probiotics is performed on blood agar plates or Columbia agar plate with 5% of sheep blood, of which sheep erythrocytes are sensitive to bacterial hemolysins. Once the tested probiotics secrete hemolysins, the hemolytic activity can be directly observed by hemolytic ring or clearing zones around the colonies on the blood agar plates. A translucent grass green hemolytic ring with incomplete clearance means the α-hemolysis activity, whereas, a colorless and transparent hemolytic ring with complete clearance refers to β-hemolysis activity.
Although hemolysis is generally detected among the pathogenic microorganisms, especially Streptococcus species, it is necessary for the safety assessment of live biotherapeutic probiotics. Currently, conducted studies showed that no hemolytic activity has been found among the probiotic Bifidobacterium species and fecal Lactobacillus species. However, Lactobacillus rhamnosus strains have been demonstrated to secrete α-hemolysin and mediate hemolytic activity in 1998 by Baumgartner.
Fig.1 α-hemolysis, β-hemolysis, and γ-hemolysis of microorganisms on the blood agar.
Aiming to find effective solutions for human health improvement, Creative Biolabs has been committed to novel live biotherapeutics for several years. Armed with the broadest range of probiotics research platforms, we offer custom solutions and detailed analytic services for probiotic drug discovery. In addition to the hemolytic activity test for the safety evaluation of probiotics, a diversity of related analytical and manufacturing services for multiple probiotics are also our highlighted services, which mainly include but not limited to:
For more detailed information, please feel free to contact us or send us an inquiry.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.